Immunecheckpointinhibitors – Head and Neck Network https://headandnecknetwork.com Thu, 06 Nov 2025 09:02:03 +0000 it-IT hourly 1 https://wordpress.org/?v=7.0.2 https://headandnecknetwork.com/wp-content/uploads/2025/01/cropped-favicon-32x32.jpg Immunecheckpointinhibitors – Head and Neck Network https://headandnecknetwork.com 32 32 IMMUNE CHECKPOINT INHIBITORS – 3RD TYPE OF IMMUNOTHERAPY https://headandnecknetwork.com/immune-checkpoint-inhibitors-3rd-type-of-immunotherapy/ https://headandnecknetwork.com/immune-checkpoint-inhibitors-3rd-type-of-immunotherapy/#respond Thu, 06 Nov 2025 09:01:17 +0000 https://headandnecknetwork.com/?p=1796 IMMUNE CHECKPOINT INHIBITORS – 3RD TYPE OF IMMUNOTHERAPY

Immune checkpoint inhibitors are a third type of immunotherapy (for other types search in the news ⬇️)

Immune checkpoints on cell surfaces help control an immune response.

Usually, immune checkpoints keep T cells inactive, that is,

in an off state, until they’re needed.

This keeps the T cells from harming normal cells.

Cancer cells can take advantage of these checkpoints to switch T cells off.

This keeps the cancer cells from being killed.

Immune checkpoint inhibitors are drugs that block the checkpoints.

This frees the T cells to attack the cancer.

These three types of immunotherapy are effective ways to treat cancer, but they don’t work

for every patient and can cause serious side effects.

Source: National Cancer Institute

Artwork and animation by Terese Winslow, LLC and Devon Medical Art, LLC

]]> https://headandnecknetwork.com/immune-checkpoint-inhibitors-3rd-type-of-immunotherapy/feed/ 0 T CELL DYNAMICS WITH NEOADJUVANT IMMUNOTHERAPY IN HEAD AND NECK CANCER https://headandnecknetwork.com/t-cell-dynamics-with-neoadjuvant-immunotherapy-in-head-and-neck-cancer/ https://headandnecknetwork.com/t-cell-dynamics-with-neoadjuvant-immunotherapy-in-head-and-neck-cancer/#respond Mon, 03 Mar 2025 14:56:34 +0000 https://headandnecknetwork.com/?p=1000

T CELL DYNAMICS WITH NEOADJUVANT IMMUNOTHERAPY IN HEAD AND NECK CANCER

Neoadjuvant immune-checkpoint inhibitors (ICIs) have been shown to be safe with promising early trial results in patients with locally advanced, resectable human papillomavirus-unrelated head and neck squamous cell carcinoma.

Immune-checkpoint inhibitors (ICIs) are being tested as neoadjuvant therapies in various solid tumours, including in patients with head and neck squamous cell carcinoma (HNSCC), with promising results.

This approach is well-tolerated with favourable clinical outcomes including promising pathological response rates in initial studies. Pathological responses are likely to be increased by combining other agents with anti-PD-(L)1 antibodies.

Data suggest that pretreatment intratumoural tissue-resident memory CD8+ T cells are key drivers of tumour regression and give rise to both local and systemic antitumour immune responses.

Analyses of systemic responses have defined a PD-1+KLRG1− circulating CD8+ T cell subpopulation that is highly predictive of response, and revealed the interrelationships between intratumoural clones and circulating CD8+ T cells.

Lastly, interrogation of T cell populations within lymph nodes is beginning to delineate the immune crosstalk between the primary tumour and tumour-draining lymph nodes and how this relationship might be disrupted with tumour infiltration of the latter.

]]> https://headandnecknetwork.com/t-cell-dynamics-with-neoadjuvant-immunotherapy-in-head-and-neck-cancer/feed/ 0